CDNA

Caredx Inc

71.52

Oct 29 • 3:59 PM ET -0.61 (-0.85%)

82.50

Aftermarket • 7:30 PM ET +10.98 (15.35%)

Healthcare Diagnostics & Research USA Mid NASD

Today, 4:11 PMCareDx beats Q3 2026 estimates with non-GAAP EPS $0.70 (+2233% YoY), revenue $139.4M (+39% YoY), raises 2026 revenue and adjusted EBITDA guidance

Peers: NTRA IMDX TMO VCYT BLLN GH CSTL WGS NEO MYGN

| Held by: VTI XBI IWM ARKG VXF IWO DFAS IBB SCHA VTWO

Scroll to Statements

Index	RUT
Market Cap	3.70B
Enterprise Value	3.35B
Income	111.01M
Sales	458.09M
Book/sh	8.27
Cash/sh	7.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	765
IPO	Jul 17, 2014

P/E	34.47
Forward P/E	55.41
PEG	1.18
P/S	8.08
P/B	8.65
P/C	9.90
P/FCF	43.68
EV/EBITDA	186.18
EV/Sales	7.30
Quick Ratio	4.51
Current Ratio	4.58
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	2.07
EPS next Y	1.29
EPS next Q	0.23
EPS this Y	106.62%
EPS next Y	7.70%
EPS next 5Y	46.93%
EPS past 3/5Y	34.67% 0.09%
Sales past 3/5Y	5.68% 14.59%
EPS Y/Y TTM	90.73%
Sales Y/Y TTM	34.41%
EPS Q/Q	1412.42%
Sales Q/Q	52.23%
Earnings	Oct 29 AMC
EPS/Sales Surpr.	174.73% 14.27%

Insider Own	8.98%
Insider Trans	-6.82%
Inst Own	99.83%
Inst Trans	0.57%
ROA	22.72%
ROE	29.49%
ROIC	25.30%
Gross Margin	70.11%
Oper. Margin	-0.40%
Profit Margin	24.23%
SMA20	6.56%
SMA50	20.97%
SMA200	114.74%
Trades

Shs Outstand	51.48M
Shs Float	47.09M
Short Float	14.26%
Short Ratio	5.22
Short Interest	6.72M
52W High	73.43 -2.60%
52W Low	14.23 402.78%
Volatility	5.30% 6.38%
ATR (14)	3.79
RSI (14)	66.67
Beta	2.57
Rel Volume	1.31
Avg Volume	1.29M
Volume	1,691,415

Perf Week	3.41%
Perf Month	10.03%
Perf Quarter	63.62%
Perf Half Y	243.68%
Perf YTD	279.62%
Perf Year	400.84%
Perf 3Y	1330.40%
Perf 5Y	40.24%
Perf 10Y	1848.77%
Recom	1.57
Target Price	65.33
Prev Close	72.13
Price	71.52
Change %	-0.85%

Consensus

Buy

Avg. Price Target

$65.33

Implied Upside

-8.7%

Analysts9incl. previous ratings

Rating Distribution5 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 02, 2026	Initiated	CCanaccord Genuity	Buy	$65	-9.1%
Aug 03, 2026	Upgrade	CCraig Hallum	Hold → Buy	$64	-10.5%
Jan 06, 2026	Downgrade	CCraig Hallum	Buy → Hold	$26	-63.6%
Aug 26, 2025	Initiated	WWilliam Blair	Mkt Perform
Jan 15, 2025	Upgrade	WWells Fargo	Underweight → Equal Weight	$28 → $24	-66.4%
Aug 28, 2024	Initiated	WWells Fargo	Underweight	$28	-60.9%
Aug 19, 2024	Upgrade	BBTIG Research	Neutral → Buy	$40	-44.1%
May 13, 2024	Downgrade	RRaymond James	Outperform → Mkt Perform
May 01, 2024	Upgrade	CCraig Hallum	Hold → Buy	$15	-79.0%
Nov 09, 2023	Upgrade	SStephens	Equal-Weight → Overweight	$10	-86.0%
Aug 15, 2023	Upgrade	RRaymond James	Mkt Perform → Outperform	$12	-83.2%
May 11, 2023	Downgrade	BBTIG Research	Buy → Neutral
Mar 07, 2023	Downgrade	SStephens	Overweight → Equal-Weight	$19 → $9	-87.4%
Mar 03, 2023	Downgrade	RRaymond James	Strong Buy → Mkt Perform
Mar 03, 2023	Downgrade	CCraig Hallum	Buy → Hold	$26 → $9	-87.4%
Apr 25, 2022	Initiated	SStephens	Overweight	$50	-30.1%
Jul 20, 2021	Resumed	BBTIG Research	Buy	$115	+60.8%
Jun 03, 2021	Initiated	GGoldman	Buy	$95	+32.8%
Feb 26, 2021	Downgrade	HH.C. Wainwright	Buy → Neutral
Oct 30, 2020	Reiterated	HH.C. Wainwright	Buy	$47 → $55	-23.1%

Today 07:01PM	CareDx Raises Guidance For A Third Straight Quarter As Transplant Volume Accelerates, But One-Time Items And A Softer Implied Q4 Temper The Beat (Earnings Whispers) +15.35%
04:42PM	CareDx: Q3 Earnings Snapshot (Associated Press)
04:01PM	CareDx Announces Third Quarter 2026 Financial Results (Business Wire)
Oct-22-26 07:05AM	CareDx Announces New KOAR Data Linking Elevated AlloSure Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 (Business Wire)
Oct-21-26 06:24PM	CareDx Faces First NavDx Quarter With Street Estimates Trailing Its Raised Outlook (Earnings Whispers)
04:01PM	Loading…
Oct-15-26 04:01PM	CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026 (Business Wire)
Sep-24-26 02:02PM	CareDx +14% on Fresh $74 Analyst Price Target (TIKR) +13.00%
Aug-07-26 04:01PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-03-26 01:57PM	SNOW, CDNA Stocks Hit Fresh 52-Week Highs Whats Driving Investor Optimism Today? (Stocktwits) +9.47%
Jul-31-26 06:45PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +14.72%
03:11PM	Medical Test Name Explodes To A High After Earnings (Investor's Business Daily)
Jul-30-26 04:22PM	CareDx: Q2 Earnings Snapshot (Associated Press) +7.60%
04:01PM	CareDx Announces Second Quarter 2026 Financial Results (Business Wire)
Jul-16-26 09:43AM	CareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA) (InvestorsHub) +35.60%
08:35AM	CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 (Business Wire)
08:30AM	Loading…
08:30AM	CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination (Business Wire)
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 04:05PM	CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology (Business Wire)
Jun-30-26 04:05PM	CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific (Business Wire)
Jun-18-26 07:05AM	CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress (Business Wire) +11.50%
Jun-16-26 04:05PM	CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology (Business Wire)
May-20-26 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-11-26 04:05PM	CareDx Announces Dismissal of 2021 Qui Tam Suit (Business Wire)
May-01-26 04:01PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-26 03:10AM	CareDx Inc (CDNA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com) -5.07%
Apr-28-26 08:41PM	CareDx to Acquire Naveris to Expand Into Cancer MRD Testing (Exec Edge)
04:18PM	CareDx: Q1 Earnings Snapshot (Associated Press)
04:05PM	CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing (Business Wire)
04:01PM	CareDx Announces First Quarter 2026 Financial Results (Business Wire)
Apr-21-26 04:01PM	CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting (Business Wire)
07:05AM	Loading…
Apr-20-26 07:05AM	CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing (Business Wire)
Apr-16-26 09:49AM	Why Diagnostics Names CareDx And QuidelOrtho Just Diverged (Investor's Business Daily) +27.60%
Apr-15-26 04:30PM	CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results (Business Wire)
Apr-14-26 04:01PM	CareDx to Report First Quarter 2026 Financial Results on April 28, 2026 (Business Wire)
Mar-07-26 05:02PM	CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference (MarketBeat)
Mar-05-26 04:01PM	CareDx Announces VANTx, an AIPowered Clinical Data & Analytics Platform Built on CareDxs Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets (Business Wire)
Feb-27-26 04:01PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-26 12:04AM	CareDx Inc (CDNA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
Feb-24-26 11:11PM	CareDx Q4 Earnings Call Highlights (MarketBeat)
08:00PM	CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:30PM	CareDx (CDNA) Q4 Earnings Miss Estimates (Zacks)
05:15PM	CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer (Business Wire)
04:21PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	CareDx Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-18-26 08:00AM	CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference (Business Wire)
Feb-16-26 11:32AM	CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT (Zacks)
Feb-13-26 01:09AM	CareDx Expands Transplant Plus Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data (MarketBeat)
Feb-12-26 07:05AM	CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy (Business Wire)
Feb-10-26 04:01PM	CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-03-26 07:05AM	CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings (Business Wire)
Jan-27-26 04:05PM	CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:30AM	Implied Volatility Surging for CareDx Stock Options (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks) +20.08%
07:05AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-07-26 07:05AM	CareDx and 10x Genomics to Launch ImmuneScape Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response (Business Wire)
Jan-06-26 10:48AM	Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now? (Zacks) -5.05%
Dec-26-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-23-25 09:15AM	Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-18-25 05:00PM	CareDx Provides Notice of Proposed Derivative Settlement (Business Wire)
Nov-27-25 09:55AM	Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade (Zacks)
Nov-24-25 04:05PM	SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation (Business Wire)
Nov-07-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.91%
Nov-06-25 08:00AM	CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025 (Business Wire) -9.20%
Nov-05-25 12:03AM	CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com) +13.84%
Nov-04-25 07:00PM	CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
05:12PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:52AM	CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 07:05AM	CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer (Business Wire)
Oct-23-25 04:05PM	CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure (Business Wire)
Oct-22-25 04:01PM	CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors (Business Wire)
Oct-21-25 08:00AM	CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-06-25 07:05AM	CareDx Announces New IVD Products and IVDR Certification for AlloSeq Tx and QTYPE at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting (Business Wire)
Sep-02-25 04:01PM	CareDx Issues Comment Letter on Draft LCD Policy (Business Wire) -8.09%
Aug-26-25 01:08PM	CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential (Benzinga)
Aug-22-25 08:30AM	Do Options Traders Know Something About CareDx Stock We Don't? (Zacks)
Aug-21-25 04:01PM	CareDx to Participate in Wells Fargo Healthcare Conference (Business Wire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire) +5.86%
Aug-06-25 06:30PM	Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings (Zacks) -7.86%
05:45PM	CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
04:43PM	CareDx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	CareDx Announces Second Quarter 2025 Financial Results (Business Wire)
12:56PM	CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation (Business Wire)
Aug-05-25 10:07AM	What To Expect From CareDx Inc (CDNA) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 04:01PM	CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress (Business Wire)
Jul-23-25 07:05AM	CareDx to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-22-25 07:06AM	CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains? (Zacks)
Jul-18-25 08:00AM	CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection (Business Wire)
Jun-03-25 04:30PM	CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire) +10.67%
May-13-25 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-01-25 03:17AM	CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments (GuruFocus.com) -10.72%
Apr-30-25 08:39PM	CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript (Seeking Alpha) -6.89%
05:50PM	CareDx (CDNA) Tops Q1 Earnings Estimates (Zacks)
04:50PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 07:05AM	CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-24-25 07:05AM	CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PETER MAAG	Director	Aug 17 '26	Proposed Sale	46.38	9,122	423,091		Aug 17 04:06 PM
PETER MAAG	Director	Aug 14 '26	Proposed Sale	45.30	7,000	317,113		Aug 14 06:09 PM
PETER MAAG	Director	Aug 13 '26	Proposed Sale	47.07	7,000	329,505		Aug 13 04:19 PM
PETER MAAG	Director	Aug 12 '26	Proposed Sale	46.89	7,000	328,238		Aug 12 04:08 PM
PETER MAAG	Director	Aug 11 '26	Proposed Sale	47.69	7,000	333,851		Aug 11 06:12 PM
PETER MAAG	Director	Aug 10 '26	Proposed Sale	47.66	6,902	328,949		Aug 10 06:23 PM
ARTHUR TORRES	Director	Aug 10 '26	Proposed Sale	47.73	4,200	200,475		Aug 10 04:17 PM
PETER MAAG	Director	Aug 07 '26	Proposed Sale	45.83	27,332	1,252,492		Aug 07 04:52 PM
Bickerstaff George	Director	Aug 05 '26	Sale	46.28	20,000	925,700	134,061	Aug 06 04:10 PM
COURNOYER CHRISTINE	Director	Aug 04 '26	Sale	46.94	16,000	750,973	42,943	Aug 06 04:10 PM
Novack Jeffrey Adam	Secretary and General Counsel	Aug 05 '26	Sale	46.26	2,688	124,349	106,075	Aug 06 04:05 PM
Goldberg Michael	Director	Aug 04 '26	Sale	47.06	44,700	2,103,497	61,738	Aug 06 04:05 PM
PETER MAAG	Director	Aug 05 '26	Proposed Sale	46.40	46,963	2,178,945		Aug 05 05:23 PM
JEFFREY NOVACK	Officer	Aug 05 '26	Proposed Sale	47.09	2,688	126,578		Aug 05 04:22 PM
GEORGE W BICKERSTAFF	Director	Aug 05 '26	Proposed Sale	46.28	20,000	925,700		Aug 05 04:15 PM
Christine M. Cournoyer	Director	Aug 04 '26	Proposed Sale	47.09	16,000	753,440		Aug 04 06:09 PM
CHRISTINE COURNOYER	Director	Aug 04 '26	Proposed Sale	47.53	31,943	1,518,142		Aug 04 04:38 PM
MICHAEL D. GOLDBERG FAM TRUST	Director	Aug 04 '26	Proposed Sale	47.06	44,700	2,103,497		Aug 04 04:28 PM
PETER MAAG	Director	Aug 04 '26	Proposed Sale	47.28	75,653	3,576,851		Aug 04 04:02 PM
Hanna John Walter JR	President and CEO	Jul 16 '26	Option Exercise	8.20	118,000	967,600	771,448	Jul 17 04:23 PM
Hanna John Walter JR	President and CEO	Jul 16 '26	Sale	37.79	118,000	4,458,637	653,448	Jul 17 04:23 PM
Valantine Hannah	Director	Jul 16 '26	Option Exercise	14.76	28,779	424,895	65,465	Jul 17 04:22 PM
Valantine Hannah	Director	Jul 16 '26	Sale	36.15	28,779	1,040,243	36,686	Jul 17 04:22 PM
JOHN WALTER HANNA	Director	Jul 16 '26	Proposed Sale	29.75	118,000	3,510,500		Jul 16 04:35 PM
HANNAH VALANTINE	Director	Jul 16 '26	Proposed Sale	29.75	28,779	856,175		Jul 16 04:33 PM
Hanna John Walter JR	President and CEO	Jun 29 '26	Option Exercise	8.20	39,900	327,180	701,859	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 15 '26	Option Exercise	8.20	15,676	128,543	661,959	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 11 '26	Option Exercise	8.20	13,618	111,668	646,283	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 04 '26	Option Exercise	8.20	706	5,789	632,665	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 26 '26	Option Exercise	8.20	100	820	662,059	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 29 '26	Sale	29.24	39,900	1,166,836	661,959	Jun 30 05:29 PM
Hanna John Walter JR	President and CEO	Jun 26 '26	Sale	29.00	100	2,900	661,959	Jun 30 05:29 PM
JOHN HANNA	Director	Jun 29 '26	Proposed Sale	28.82	39,500	1,138,390		Jun 29 04:42 PM
Hanna John Walter JR	President and CEO	Jun 15 '26	Sale	24.03	17,683	424,877	631,959	Jun 17 04:05 PM
Valantine Hannah	Director	Jun 15 '26	Sale	23.11	12,103	279,728	36,686	Jun 16 05:51 PM
Hanna John Walter JR	President and CEO	Jun 11 '26	Sale	24.02	21,998	528,443	649,642	Jun 15 05:06 PM
HANNAH VALANTINE	Director	Jun 15 '26	Proposed Sale	22.97	12,103	278,006		Jun 15 04:59 PM
JOHN HANNA	Director	Jun 11 '26	Proposed Sale	23.46	40,181	942,646		Jun 11 04:24 PM
Hanna John Walter JR	President and CEO	Jun 04 '26	Sale	24.00	4,835	116,045	671,640	Jun 08 04:05 PM
JOHN WALTER HANNA	Director	Jun 04 '26	Proposed Sale	22.31	4,835	107,869		Jun 04 04:32 PM
TORRES ARTHUR A	Director	May 15 '26	Sale	19.89	6,484	128,978	38,665	May 18 04:05 PM
TORRES ARTHUR A	Director	May 14 '26	Sale	20.97	4,086	85,698	45,149	May 18 04:05 PM
ARTHUR TORRES	Director	May 15 '26	Proposed Sale	19.89	6,484	128,978		May 15 04:46 PM
ARTHUR TORRES	Director	May 14 '26	Proposed Sale	20.97	4,086	85,698		May 14 06:44 PM
Novack Jeffrey Adam	Secretary and General Counsel	May 05 '26	Sale	20.68	2,688	55,581	113,924	May 06 04:05 PM
JEFFREY NOVACK	Officer	May 05 '26	Proposed Sale	20.96	2,688	56,340		May 05 04:32 PM
Hanna John Walter JR	President and CEO	Apr 16 '26	Sale	21.12	10,282	217,156	676,475	Apr 20 04:53 PM
JOHN HANNA	Director	Apr 16 '26	Proposed Sale	17.57	10,282	180,655		Apr 16 04:12 PM
Goldberg Michael	Director	Mar 31 '26	Option Exercise	3.35	26,500	88,648	183,961	Apr 01 04:10 PM
Novack Jeffrey Adam	Secretary and General Counsel	Feb 03 '26	Sale	20.56	4,441	91,286	125,364	Feb 04 04:22 PM
JEFFREY NOVACK	Officer	Feb 03 '26	Proposed Sale	20.42	4,441	90,685		Feb 03 04:33 PM
Hanna John Walter JR	President and CEO	Jan 22 '26	Sale	21.16	19,280	408,023	597,405	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 21 '26	Sale	21.00	200	4,200	616,685	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 15 '26	Sale	21.05	10,156	213,804	616,885	Jan 20 05:30 PM
JOHN HANNA	Director	Jan 15 '26	Proposed Sale	20.32	29,636	602,204		Jan 15 04:40 PM
Novack Jeffrey Adam	Secretary and General Counsel	Dec 04 '25	Sale	19.17	7,293	139,804	97,925	Dec 05 04:07 PM
JEFFREY NOVACK	Officer	Dec 04 '25	Proposed Sale	18.85	7,293	137,473		Dec 04 04:39 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 07 '25	Sale	15.52	2,688	41,723	105,218	Nov 10 04:14 PM
Jeffrey Adam Novack	Officer	Nov 07 '25	Proposed Sale	15.01	2,688	40,347		Nov 07 04:37 PM
ABHISHEK JAIN	Officer	Nov 05 '25	Proposed Sale	15.77	53,388	842,050		Nov 05 04:21 PM
ABHISHEK JAIN	Officer	Oct 31 '25	Proposed Sale	14.90	9,964	148,464		Oct 31 04:48 PM

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

PresidentMr. John Walter Hanna Jr.

CPAMr. Keith S. Kennedy C.F.A.

General Counsel & SecretaryMr. Jeffrey A. Novack

Chief Commercial OfficerMs. Jessica Meng

Chief Technology OfficerMr. Kashif Rathore

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDNA

Caredx Inc

Upgrade your Finviz experience